Abstract
P44 Phase 1 study of PGN-EDO51 demonstrates tolerability, delivery and high levels of exon skipping for treatment of Duchenne muscular dystrophy (DMD)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have